Frederique Ph.D. Menzaghi - Feb 1, 2024 Form 4 Insider Report for Cara Therapeutics, Inc. (CARA)

Signature
/s/ Darren DeStefano, Attorney-in-Fact
Stock symbol
CARA
Transactions as of
Feb 1, 2024
Transactions value $
$0
Form type
4
Date filed
2/5/2024, 04:28 PM
Previous filing
Jun 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CARA Common Stock Award $0 +13.5K +8.78% $0.00 167K Feb 1, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Frederique Ph.D. Menzaghi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents the number of shares that vested under a performance-based restricted stock unit award (the "Award") granted on March 1, 2023 based on the Issuer's satisfaction of certain performance criteria of the Award. In light of the performance-based vesting conditions of the Award, such shares were not reportable under Section 16 until vesting was determined. On February 1, 2024, the Compensation Committee of the Issuer's Board of Directors certified a 50% level of achievement against the Award's performance goals.